157 related articles for article (PubMed ID: 26571416)
21. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
[TBL] [Abstract][Full Text] [Related]
22. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
Lee FT; Hall C; Rigopoulos A; Zweit J; Pathmaraj K; O'Keefe GJ; Smyth FE; Welt S; Old LJ; Scott AM
J Nucl Med; 2001 May; 42(5):764-9. PubMed ID: 11337573
[TBL] [Abstract][Full Text] [Related]
23. A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
Kobayashi K; Sasaki T; Takenaka F; Yakushiji H; Fujii Y; Kishi Y; Kita S; Shen L; Kumon H; Matsuura E
J Immunol Res; 2015; 2015():268172. PubMed ID: 25883990
[TBL] [Abstract][Full Text] [Related]
24. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
25. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
26. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
27. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
28. Immuno-PET Imaging to Assess Target Engagement: Experience from
Menke-van der Houven van Oordt CW; McGeoch A; Bergstrom M; McSherry I; Smith DA; Cleveland M; Al-Azzam W; Chen L; Verheul H; Hoekstra OS; Vugts DJ; Freedman I; Huisman M; Matheny C; van Dongen G; Zhang S
J Nucl Med; 2019 Jul; 60(7):902-909. PubMed ID: 30733323
[TBL] [Abstract][Full Text] [Related]
29. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts.
El-Sayed A; Bernhard W; Barreto K; Gonzalez C; Hill W; Pastushok L; Fonge H; Geyer CR
Theranostics; 2018; 8(17):4856-4869. PubMed ID: 30279742
[No Abstract] [Full Text] [Related]
31. Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.
Lange SE; Zheleznyak A; Studer M; O'Shannessy DJ; Lapi SE; Van Tine BA
Oncotarget; 2016 Mar; 7(11):13082-92. PubMed ID: 26909615
[TBL] [Abstract][Full Text] [Related]
32. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
33. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
34. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
35. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Higashikawa K; Yagi K; Watanabe K; Kamino S; Ueda M; Hiromura M; Enomoto S
PLoS One; 2014; 9(11):e109866. PubMed ID: 25365349
[TBL] [Abstract][Full Text] [Related]
36. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
37. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
38. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
39. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H
Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030
[TBL] [Abstract][Full Text] [Related]
40. Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.
Wehrenberg-Klee E; Turker NS; Heidari P; Larimer B; Juric D; Baselga J; Scaltriti M; Mahmood U
J Nucl Med; 2016 Sep; 57(9):1413-9. PubMed ID: 27081168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
